Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Posts Revenue Boost, Narrowed Net Loss for Fourth Quarter

NEW YORK, Feb. 24 - Gene Logic posted a jump in revenues for the fourth quarter of 2002 today, accompanied by increased R&D expenses and narrowing net losses.


The company's revenues for the fourth quarter were $14.8 million, an increase of 6 percent over the $14.0 million reported in the year-ago period. Gene Logic attributed the revenue increase to new and renewed subscriptions for its GeneExpress database.


Higher depreciation and amortization expenses, new software and database releases, and tissue acquisition costs drove the company's total operating expenses to $19.4 million, up from $18.5 million year-over-year. Gene Logic posted research and development expenses of $14.7 million for the quarter, up from $14.0 million in the same period of 2001.


The company's fourth-quarter 2002 net loss of $5.2 million, or $0.19 per share, shrank slightly compared to its net loss of $6.0 million, or $0.22 per share, for the same period of 2001.


As of December 31, 2002, Gene Logic had $107 million in cash and cash equivalents, compared to $128 million in the year-ago period. The company also holds $60 million in marketable securities available for sale, down from $70 million in the fourth quarter of 2001.


Full details are available here.

The Scan

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.